 3. Use of any investigational drug 21 days to the start of treatment or 5 half-lives whichever is shorter prior to the first dose of INC280 with bevacizumab. For study drugs for which 5 half-lives is 21 days, a minimum of 10 days between termination of the study drug and the start of treatment is required. 